130 related articles for article (PubMed ID: 35715367)
1. Re: J. Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol 2022;81:331-6: Novel Insights into Evidence of Metastatic Urothelial Carcinoma Transcriptomic Subtype.
Song Y; Qin C; Xu T
Eur Urol; 2022 Sep; 82(3):e76-e77. PubMed ID: 35715367
[No Abstract] [Full Text] [Related]
2. Reply to Yuxuan Song, Caipeng Qin, and Tao Xu's Letter to the Editor re: J. Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol 2022;81:331-6.
Nakauma-González JA; Rijnders M; van de Werken HJG; Lolkema MPJ; Boormans JL
Eur Urol; 2022 Sep; 82(3):e78-e79. PubMed ID: 35717359
[No Abstract] [Full Text] [Related]
3. Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40.
Gevaert T; Eckstein M; Montironi R; Lopez-Beltran A
Eur Urol; 2019 Jun; 75(6):e162-e163. PubMed ID: 30712970
[No Abstract] [Full Text] [Related]
4. Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40.
Rijnders M; van der Veldt AAM; de Wit R; van Leenders GJLH
Eur Urol; 2019 Jun; 75(6):e160-e161. PubMed ID: 30723047
[No Abstract] [Full Text] [Related]
5. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
Nakauma-González JA; Rijnders M; van Riet J; van der Heijden MS; Voortman J; Cuppen E; Mehra N; van Wilpe S; Oosting SF; Rijstenberg LL; Westgeest HM; Zwarthoff EC; de Wit R; van der Veldt AAM; van de Werken HJG; Lolkema MPJ; Boormans JL
Eur Urol; 2022 Apr; 81(4):331-336. PubMed ID: 35086719
[TBL] [Abstract][Full Text] [Related]
6. The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.
Ohara K; Rendeiro AF; Bhinder B; Eng KW; Ravichandran H; Nguyen D; Pisapia D; Vosoughi A; Fernandez E; Shohdy KS; Manohar J; Beg S; Wilkes D; Robinson BD; Khani F; Bareja R; Tagawa ST; Ouseph MM; Sboner A; Elemento O; Faltas BM; Mosquera JM
Nat Commun; 2024 Mar; 15(1):2009. PubMed ID: 38499531
[TBL] [Abstract][Full Text] [Related]
7. Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313-7.
Cheng C; Hu J; Chen J
Eur Urol; 2023 Jun; 83(6):e159-e160. PubMed ID: 36967357
[No Abstract] [Full Text] [Related]
8. Re: Comprehensive Genomic Profiling of 295 Cases of Clinically Advanced Urothelial Carcinoma of the Urinary Bladder Reveals a High Frequency of Clinically Relevant Genomic Alterations.
Liedberg F
Eur Urol; 2016 Aug; 70(2):400-1. PubMed ID: 27353966
[No Abstract] [Full Text] [Related]
9. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
[TBL] [Abstract][Full Text] [Related]
10. Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017: Focus on Our Personal Recollections and Observations.
Montironi R; Scarpelli M; Cimadamore A; Mikuz G
Eur Urol Focus; 2022 May; 8(3):882-884. PubMed ID: 33994166
[No Abstract] [Full Text] [Related]
11. Genomics in upper tract urothelial carcinoma.
Kammerer-Jacquet SF; Mathieu R; Peyronnet B; Rioux-Leclercq N; Bensalah K
Curr Opin Urol; 2017 Jan; 27(1):35-40. PubMed ID: 27584028
[TBL] [Abstract][Full Text] [Related]
12. Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7.
Mullane SA; Bellmunt J
Eur Urol; 2016 Sep; 70(3):e71. PubMed ID: 26852077
[No Abstract] [Full Text] [Related]
13. Molecular Pathology of Urothelial Carcinoma.
Al-Ahmadie H; Netto GJ
Surg Pathol Clin; 2021 Sep; 14(3):403-414. PubMed ID: 34373092
[TBL] [Abstract][Full Text] [Related]
14. Reply to Rodolfo Montironi, Marina Scarpelli, Alessia Cimadamore, and Gregor Mikuz's Letter to the Editor re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017. Focus on Our Personal Recollections and Observations.
van der Kwast T; Van Rhijn B; Kamat A; Cheng L
Eur Urol Focus; 2022 May; 8(3):885-886. PubMed ID: 33992577
[No Abstract] [Full Text] [Related]
15. Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95-108.
Feng YN; Xie GY; Xiao L
Eur Urol; 2023 Dec; 84(6):e145. PubMed ID: 37659959
[No Abstract] [Full Text] [Related]
16. Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: a paradigm for molecular subtyping of urothelial cell carcinoma of the bladder.
Adam RM; DeGraff DJ
Urol Oncol; 2015 Oct; 33(10):444-50. PubMed ID: 26254697
[TBL] [Abstract][Full Text] [Related]
17. Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14.
Orsola A; Cecchini L; Morote J
Eur Urol; 2009 Jan; 55(1):e15-6; author reply e17-8. PubMed ID: 18692301
[No Abstract] [Full Text] [Related]
18. Re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61.
Herr H
Eur Urol; 2017 Jun; 71(6):e171-e172. PubMed ID: 27979427
[No Abstract] [Full Text] [Related]
19. Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15: Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer.
Roumiguie M; Contreras-Sanz A; Black PC
Eur Urol; 2021 Jun; 79(6):e182-e183. PubMed ID: 33838962
[No Abstract] [Full Text] [Related]
20. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
